-
CUE Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Cue Biopharma (CUE)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.57 mm | 32.57 mm | 32.57 mm | 32.57 mm | 32.57 mm | 32.57 mm |
Cash burn (monthly) | (no burn) | 1.71 mm | 2.94 mm | 3.61 mm | 2.51 mm | 2.93 mm |
Cash used (since last report) | n/a | 8.67 mm | 14.93 mm | 18.33 mm | 12.75 mm | 14.86 mm |
Cash remaining | n/a | 23.90 mm | 17.64 mm | 14.24 mm | 19.82 mm | 17.71 mm |
Runway (months of cash) | n/a | 14.0 | 6.0 | 3.9 | 7.9 | 6.1 |
13F holders | Current |
---|---|
Total holders | 56 |
Opened positions | 12 |
Closed positions | 7 |
Increased positions | 19 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 12.55 bn |
Total shares | 12.68 mm |
Total puts | 1.20 k |
Total calls | 22.00 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Bleichroeder | 5.00 mm | $5.45 bn |
Vanguard | 2.06 mm | $2.24 bn |
Slate Path Capital | 918.84 k | $1.25 mm |
BlackRock | 638.95 k | $696.46 mm |
Geode Capital Management | 631.28 k | $688.25 mm |
Robertson Stephens Wealth Management | 478.50 k | $521.57 mm |
Sigma Planning | 447.18 k | $487.42 mm |
Good Life Advisors | 400.00 k | $436.00 mm |
BAC Bank of America | 324.32 k | $353.50 mm |
Advisory Research | 257.23 k | $280.38 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 25 | Driscoll Frederick W | Stock Option Common Stock | Grant | Acquire A | No | No | 1.09 | 24,400 | 26.60 k | 24,400 |
2 Jan 25 | Pamela Garzone | Stock Option Common Stock | Grant | Acquire A | No | No | 1.09 | 24,400 | 26.60 k | 24,400 |
2 Jan 25 | Kiener Peter A | Stock Option Common Stock | Grant | Acquire A | No | No | 1.09 | 24,400 | 26.60 k | 24,400 |
2 Jan 25 | Morich Frank | Stock Option Common Stock | Grant | Acquire A | No | No | 1.09 | 24,400 | 26.60 k | 24,400 |
2 Jan 25 | Patrick Verheyen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.09 | 24,400 | 26.60 k | 24,400 |